PATENT CLAIM ANALYSIS

Application Number: 16060020
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["424", "186100"]

Abstract:
Cancer immunotherapy is enhanced by co-expression of cancer associated or tumor-specific (neo)epitopes with co-stimulatory molecules and/or other immune activators. Where desired, treatment may be enhanced by administration of a immune checkpoint inhibitor.

Claim (Index 6):
The method of anyone of the preceding claims further comprising a step of predicting the HLA type of the patient in silico.

Metadata:
- Claim Count in Document: 61.0
- Percentile: 94.0
- Lexical Diversity: 1.15152
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15366838', '15291911', '15291516', '14247298', '15387199']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6583289638199094
- 35 USC 102 Novelty (BERT): 0.5561538060340554
- Combined Prediction Score: 0.6481114480413239
- Mean Citation Score: 286.4204180000001
- Max Citation Score: 412.73987
- Similarity Product: 337.8090269981855

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test